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Mitofusin activation enhances 
mitochondrial motility and promotes 
neuroregeneration in CMT2A
Human brains represent only 2% of body 
mass, but their high relative metabolic 
activity accounts for ~20% of total body 
adenosine triphosphate (ATP) consumption. 
ATP generated by neuronal mitochondria 
fuels nerve signaling and homeostatic repair. 
In the peripheral nervous system, which 
has greater capacity for regeneration after 
physical, toxic or genetic injury than the 
central nervous system, ATP also powers 
actin polymerization/depolymerization for 
growth cone formation and axon extension. 
Mitochondrial ATP generation is therefore a 
central component of neuronal functioning 
in the central and peripheral nervous 
systems.
T h e  c o n t e x t u a l  r o l e s  o f  n e u r o n a l 
mitochondria are largely determined by two 
factors, the fitness of individual organelles 
and their localization within host neurons. 
The role of mitochondrial fitness is widely 
acknowledged: healthy mitochondria 
perform their ATP-producing function 
without compromising host  neurons, 
whereas damaged mitochondria in which the 
respiratory chain is partially uncoupled from 
ATP production elaborate cytotoxic reactive 
oxygen species (ROS) that both damage the 
host neuron and can activate programmed 
cel l  death pathways.  By comparison, 
the role of mitochondrial transport and 
localization has only recently become widely 
appreciated: almost all ~1000 mitochondrial 
proteins (i.e. except the 13 respiratory chain 
proteins encoded by the mitochondrial 
genome) are encoded by nuclear genes 
and synthesized by host cell ribosomes. 
Therefore, mitochondrial biogenesis takes 
place primarily in neuronal soma and newly 
formed mitochondria in the cell body are 
actively directed to distal areas of neuronal 
activity, such as synapses and growth 
cones. The unique architecture of neurons, 
especially long motor neurons innervating 
upper and lower extremities, requires that 
mitochondria traverse approximately 1 meter 
of axon length from neuronal soma in the 
spine to peripheral neuromuscular junctions. 
Damaged or senescent mitochondria in 
synapses or growth buds likewise require 
export for mitophagic elimination, which 
is necessary to prevent mitochondrial-
mediated ROS cytotoxicity at distal nerves. 
Thus, an interruption in mitochondrial 
transport might be as consequential to 
neuronal health as, and can contribute to, 
impaired mitochondrial fitness. Recently, 
Franco et al. (2020) demonstrated that 
directly enhancing mitochondrial trafficking 
within neuronal axons helps regenerate 
peripheral nerve damage in a mouse model 
of the rare sensorimotor neuropathy, 
Charcot-Marie-Tooth disease type 2A 
(CMT2A). These studies provide critical in 
vitro and in vivo support mechanistically 
linking mitochondrial trafficking to neuronal 
regeneration. 
Two  g e n e t i c  n e u ro p at h i e s  s e r ve  a s 
prototypical neurodegenerative diseases 
having mitochondrial dysfunction: Familial 
amyotrophic lateral sclerosis caused by 
mutations of superoxide dismutase 1 (SOD1) 
is an example of loss of mitochondrial fitness 
(Wong et al., 1995), in this case precipitated 
by increased neuronal ROS levels. CMT2A 
caused by mutations of mitofusin 2 (MFN2) 
is an example of interrupted mitochondrial 
transport (Baloh et al., 2007), although the 
precise mechanism by which dysfunction 
of a mitochondrial fusion protein impairs 
mitochondrial trafficking remains unclear. 
MFN2 and closely related MFN1 were 
originally described as proteins mediating 
mammalian outer mitochondrial membrane 
fusion (Dorn, 2019).  MFN2 also plays 
important roles in mitophagy (the selective 
elimination of damaged mitochondria via 
autophagy pathways) (Chen and Dorn, 
2013) and axonal mitochondrial transport 
(Rocha et al., 2018). The observations 
that mitochondrial motility is impaired 
in CMT2A caused by MFN2  mutations 
(Baloh et al.,  2007), and that CMT2A-
associated mitochondrial dysmotility can 
be reversed by small molecule mitofusin 
activators (Rocha et al., 2018), suggested 
t h a t  p h a r m a c o l o g i c a l  a c t i va t i o n  o f 
endogenous normal MFN1 and MFN2 might 
overcome mutant MFN2 suppression of 
normal mitofusin functioning in autosomal 
dominant CMT2A. While conceptually 
s imple,  the putative mechanist ic l ink 
between  mi to fus in  dysfunct ion  and 
disease progression in CMT2A has at least 
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4 degrees of separation: (1) MFN1/MFN2-
mediated mitochondrial fusion and motility 
are  suppressed by  dominant  CMT2A 
MFN2 mutants; (2) transport of healthy 
mitochondria to, and damaged mitochondria 
away from, neuromuscular junctions is 
diminished; (3) neuromuscular signaling is 
consequently impaired; (4) motor nerves 
die back from muscles; and (5) muscle mass 
decreases due to neurogenic atrophy. This 
pathophysiological complexity confounded 
expectations of whether mitofusin activation 
could reverse disease in vivo. 
In testing the idea of activating endogenous 
normal mitofusins in CMT2A Franco et al. 
(2020) developed three major objectives. 
The first was to assess the relevance of 
mitofusin activation in human CMT2A by 
replicating in human CMT2A patient neurons 
previous observations that mitofusin 
act ivat ion can reverse mitochondrial 
dysmotility in mouse CMT2A nerve axons 
(Franco et al., 2016; Rocha et al., 2018; Dang 
et al., 2020). Because iPSC-derived neurons 
lose characteristic CMT2A mitochondrial 
phenotypes (e.g. fragmentation from loss 
of fusion and stasis from loss of motility), 
Franco et al. (2020) used microRNA-mediated 
neuronal conversion to directly reprogram 
CMT2A patient dermal fibroblasts having four 
different MFN2 mutations into HB9/MNX1-
positive motor neurons. Reprogramming 
efficiency was > 90% neurons (β-III tubulin 
positive) and > 85% motor neurons (HB9 
posit ive)  in  both normal  and CMT2A 
cells. Compared to reprogrammed motor 
neurons from multiple normal subjects, all 
four CMT2A motor neuron lines exhibited 
hallmark mitochondrial fragmentation 
(loss of fusion), depolarization (impaired 
respiratory function), and dysmotil ity 
(measured as the proportion and velocity 
of motile mitochondria). Notwithstanding 
different genetic mechanisms for MFN2 
dysfunction (two mutations within the 
MFN2 GTPase domain and two within the 
MFN2 coiled-coiled hydrophobic core), 
al l  four reprogrammed CMT2A motor 
neuron lines responded to addition of 
a small molecule mitofusin activator by 
normalizing mitochondrial morphology, 
polarization status and motility. Thus, 
human CMT2A neurons, like CMT2A mouse 
neurons, respond to mitofusin activation by 
reversing prototypical mitochondrial disease 
phenotypes. Moreover, in this small sample 
the benefit on mitochondria appeared to be 
agnostic to causal MFN2 mutation. 
The second goal of Franco et al. (2020) 
was to establish efficacy in an in vivo 
mouse CMT2A model similar to the human 
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condition. Because there were no published 
CMT2A mouse models that reproduce 
the time course of disease progression, 
pattern of neuromuscular dysfunction, 
neuroelectrophysiological features, and 
histological/ultrastructural characteristics of 
human CMT2A in the absence of confounding 
developmental defects (Dorn, 2020), they 
generated a new model by combining motor 
neuron specific Mnx1-Cre and flox-stop 
human MFN2-T105M transgenes (Franco 
et al., 2020). The resulting mice express 
mutant human (h) MFN2 T105M in mouse 
motor neurons, but the Cre that evokes 
mutant MFN2 expression is extinguished 
after the first week of life, and is therefore 
not a continuing variable. Paralleling the 
human pattern of childhood onset with 
disease progression into young adulthood, 
CMT2A hMFN2 T105M mice were normal 
up to 10 weeks of age and then exhibited 
a progressive decline in neuromuscular 
function (measured as RotaRod latency) 
from 20 to 30 weeks, after which the 
disease stabilized. Human CMT2A is clinically 
distinguished from more common CMT1 
by neuroelectrophysiologic testing showing 
decreased amplitude of compound muscle 
action potentials (reflecting loss of neurons) 
without decreased nerve conduct ion 
velocity (because in CMT2A there is no loss 
of myelin); this was also recapitulated in 
MFN2 T105M mice. Finally, the characteristic 
histological and ultrastructural features of 
CMT2A were reproduced in hMFN2 T105M 
mice. Remarkably, daily intramuscular 
injection of the mitofusin activator trans-
MiM111 to mice having the full-fledged 
CMT2A phenotype reversed all of these 
abnormalities within 8 weeks (Franco et al., 
2020).
The final goal of Franco et al. (2020) was 
to elucidate mechanisms for observed 
CMT2A phenotype reversal after mitofusin 
activation. As currently understood, the 
pathophysiology of forearm and foreleg 
neuromuscular degeneration caused by 
loss-of-function MFN2 mutations in CMT2A 
consists of  the fol lowing: (1)  genetic 
mitochondrial dysfunction and dysmotility 
leads to a dearth of healthy mitochondria 
at  neuromuscular  junct ions;  (2)  th is 
compromises neuromuscular signaling and 
evokes distal neuron die-back; and 3. the 
end result is neurogenic muscular atrophy 
(Figure 1). If this is correct, then restoration 
of function in mitofusin activator-treated 
CMT2A mice implies that the neurons which 
had previously died back were regenerated, 
thus reestablishing neuromuscular integrity. 
Alternately, restoration of mitochondrial 
fus ion alone might have engendered 
neuroprotective effects. However, in support 
of a connection between mitochondrial 
trafficking and neuronal regeneration, 
enhancing mitochondr ia l  mot i l i ty  by 
genetically ablating the neuronal anchoring 
protein syntaphilin was previously shown to 
promote neuronal regrowth after physical 
injury (Zhou et al., 2016). 
Franco et al. (2020) performed a series of 
in vivo and in vitro experiments to more 
fully understand the connection between 
m i to f u s i n  a c t i vat i o n ,  m i to c h o n d r i a l 
t ransport/ loca l izat ion,  and neuronal 
regeneration. Reasoning that impaired 
mitochondrial trafficking to neuromuscular 
junctions and neuronal die-back in CMT2A 
would result in a decreased mitochondrial 
occupancy of junctional synapses and a 
reduced total number of junctional synapses, 
respectively, they used immunohistology 
to quantify junctional synapses (anti-
acetylcholine receptor) and their resident 
mitochondria (anti-cytochrome oxidase IV) 
in mouse foreleg muscles. Consistent with 
a link between mitochondrial trafficking 
and neuronal regrowth, tibialis muscles 
of vehicle-treated CMT2A mice had fewer 
than half the normal number of junctional 
synapses per muscle myocyte, and only ~half 
the normal density of mitochondria within 
those synapses; mitofusin activation reversed 
both of those abnormal metrics (Franco et 
al., 2020).
The above result supported the thesis 
that mitofusin activation promotes neuron 
regeneration in CMT2A, but the in vivo 
data were entirely correlative. Moreover, 
t h e  o b s e r ve d  re l a t i o n s h i p  b e t we e n 
mitochondrial localization within junctional 
synapses and enhanced mitochondrial 
motility is inferential. Therefore, Franco et 
al. (2020) isolated dorsal root ganglion (DRG) 
neurons from mice carrying the hMFN2 
T105M flox-stop allele, activated the mutant 
MFN2 transgene in vitro using adenoviral 
Cre, and measured DRG outgrowth in 
the presence or absence of the mitofusin 
activator. (Note, in vitro activation of hMFN2 
T105M with adeno-Cre was necessary for this 
experiment because DRGs contain sensory 
neurons and the MNX1/HB9 promoter used 
in vivo drives predominantly motor neuron 
expression.) The CMT2A DRG platform 
permitted live cell studies of mitochondrial 
aspect ratio (an indirect measure of fusion), 
mitochondrial motility and residency within 
axonal termini (linking axonal transport to 
distal neuron localization), and axon growth/
branching (a metric of axon regeneration 
after isolation and plating), which was not 
possible in fixed tissue. Mitofusin activation 
strikingly improved each of the measured 
endpoints, normalizing mitochondrial aspect 
ratio, motility and distal axon residency, and 
markedly accelerating axonal outgrowth. 
Importantly, the time courses of these 
responses, in which motility was maximized 
only 2 hours after mitofusin activation and 
axonal outgrowth was markedly accelerated 
within 24 hours, but mitochondrial fusion 
was corrected only after 48 hours, supported 
a causal relationship between mitochondrial 
transport and neuronal regrowth (Franco et 
al., 2020).
Finally, because de novo DRG axon outgrowth 
might be mechanistically distinct from axon 
regrowth after injury in CMT2A, Franco et 
al. (2020) isolated neonatal cortical neurons 
from hMFN2 T105M flox-stop mice and 
cultured the neurons in wells connected 
Figure 1 ｜ Schematic depiction of relationship between mitochondrial transport, neuron die-back, 
and neuron regeneration in CMT2A. 
Normal nerves (top) have bidirectional mitochondrial transport that delivers healthy organelles to 
and removes damaged organelles from, nerve termini. In CMT2A nerves (middle) interruption of 
distal mitochondrial transport impairs nerve function and repair, prompting dying back of the termini. 
Restoration of mitochondrial transport by activated mitofusins (bottom) promotes nerve regeneration 
that reverses in vivo neuromuscular dysfunction. CMT2A: Charcot-Marie-Tooth disease type 2A. 
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to empty wells by linear microchannels. 
Cortical neuron outgrowth resulted in long, 
non-branching axons that grew through the 
microchannels into the empty wells, wherein 
they underwent terminal branching. This 
in vitro arrangement mimics in vivo neuron 
architecture of soma, linear axon body 
and distal branched axon. Because mouse 
CMT2A neurons grow very poorly (as in the 
above DRG studies), adeno-Cre was used 
to induce hMFN2 T105M expression after 
the cultured cortical neurons had grown 
through the microchannels and developed 
complex arborizations (i.e., 10 days in vitro). 
In this way, mature CMT2A neurons were 
created that subsequently underwent distal 
aspiration axotomy, amputating the distal 
branched axons while leaving the proximal 
linear axons intact. Amputated neurons 
were maintained in culture in the presence 
or absence of mitofusin activator and early 
mitochondrial readouts of fusion (aspect 
ratio) and motility (% motile and velocity) 
were related to axon regrowth after 3 days. 
Mitochondrial aspect ratio was not affected 
by axotomy, whereas mitochondrial motility 
in CMT2A neurons (already diminished 
by half  compared to normal  neurons 
treated identically) was further reduced 
after axotomy, but restored by mitofusin 
activation. Importantly, axon regrowth in 
CMT2A neurons was doubled by mitofusin 
activation. 
These studies are the first to mechanistically 
l i nk  mi to fus in  ac t i vat ion ,  enhanced 
mitochondrial transport to distal regions 
of the neuron, and accelerated neuronal 
regeneration. The novel in vitro and in 
vivo  CMT2A disease models employed 
in these studies integrated loss of MFN2 
function with restoration of function to 
demonstrate a central role for mitofusins 
in mitochondrial motility. The underlying 
principle is that accelerated regeneration 
of damaged nerves can be achieved by 
facilitating delivery of healthy mitochondria 
to, and damaged mitochondria away from, 
terminal axon growth areas. Indeed, this 
paradigm may apply to other genetic 
neurodegenerative diseases, including 
amyotrophic lateral sclerosis, Huntington’s 
disease, Parkinson’s disease, wherein 
abnormalities of mitochondrial structure, 
transport and/or function contribute to 
observed neuropathology (Knott et al., 
2008). In these conditions we envision a 
vicious pathophysiologic cycle wherein 
pr imary  genet ic  mutat ions  encoding 
diverse proteins that directly or indirectly 
damage mitochondria evoke oxidative stress 
and mitotoxicity, resulting in additional 
mitochondrial damage and a feedback loop 
that culminates in metabolic insufficiency 
from mitochondrial drop-out and neuronal 
death from mitochondrial pathway apoptosis. 
According to this scenario, interrupting the 
cycle at any point could prove therapeutic. 
Thus, interventions like mitofusin activation 
that  promote genera l  mitochondr ia l 
resistance to an array of noxious insults may 
have broad therapeutic utility.     
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